SomaLogic, Inc. (NASDAQ:SLGC) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET

Company Participants

Marissa Bych - IR, Gilmartin Group LLC

Roy Smythe - Chief Executive Officer

Shaun Blakeman - Chief Financial Officer

Conference Call Participants

Dan Brennan - Cowen

Brandon Couillard - Jefferies

Dan Arias - Stifel

Kyle Mikson - Canaccord

Operator

Good day, and thank you for standing by. Welcome to the SomaLogic's Q2 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]

And I would now like to hand the conference over to your speaker today, Ms. Marissa Bych. Ms. Bych, please go ahead.

Marissa Bych

Hi, thank you. Today, SomaLogic released financial results for the quarter ended June 30, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that relates to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our market opportunity, gross margin, and future financial performance, protein content, and database growth, customer base, diagnostic pipeline, expectations for hiring, and growth in our organization are based upon our current estimates and various assumptions.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements for a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Form 10-Q filed with the Securities and Exchange Commission today and a section entitled Risk Factors in our most recent annual report on Form 10-K.

This conference call contains time-sensitive information and is actuate only as of the live broadcast today, August 15, 2022. SomaLogic disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise.

And with that, I will turn the call over to Roy Smythe, Chief Executive Officer.

Roy Smythe

Thank you Marissa. Good afternoon and welcome to our 2022 second quarter update call. As always, I want to express my sincere gratitude to all who continue to invest in and support us. At SomaLogic, we continue to make progress toward building a differentiated, scalable and durable proteomics enterprise. Despite a challenging and ultimately disappointing quarter, our confidence in our technology and its trajectory and its unique ability to successfully unlock the power of the proteome for our customers and society at large remains unchanged.